SUPPLEMENTARY DATA

Supplementary Table S1. Absolute 24-h and postprandial plasma concentrations of glucose, glucagon, and triglycerides

	Pramlintide + insulin (*n* = 26)	Placebo + insulin (*n* = 26)	*P* value for difference
Glucose, mmol/L*h			
$AUC_{0–24h}$	215.4 (191.6–239.2)	243.8 (220.0–267.6)	0.0258
Dinner ($AUC_{0–2h}$)	18.0 (15.2–20.7)	23.2 (20.5–26.0)	0.0091
Breakfast ($AUC_{0–2h}$)	19.1 (16.3–21.9)	23.5 (20.8–26.3)	0.0057
Lunch ($AUC_{0–3h}$)	28.3 (23.5–33.2)	36.2 (31.4–41.0)	0.0013
Glucagon, pmol/L*h			
$AUC_{0–24h}$	481.6 (436.8–531.1)	506.3 (459.1–558.3)	0.1015
Dinner ($AUC_{0–2h}$)	40.2 (36.1–44.8)	43.2 (38.7–48.1)	0.0618
Breakfast ($AUC_{0–2h}$)	38.7 (35.1–42.7)	46.2 (42.0–50.8)	0.0005
Lunch ($AUC_{0–3h}$)	62.5 (56.7–68.9)	69.9 (63.5–77.0)	0.0022
Triglycerides, mmol/L*h			
$AUC_{0–24h}$	19.4 (17.7–21.2)	21.3 (19.5–23.3)	0.0065
Dinner ($AUC_{0–2h}$)	1.5 (1.3–1.6)	1.8 (1.6–2.0)	0.0010
Breakfast ($AUC_{0–2h}$)	1.5 (1.3–1.7)	1.7 (1.5–1.9)	0.0241

Data are least-squares mean (95% CI).

AUC, area under the concentration–time curve.

SUPPLEMENTARY DATA

Supplementary Table S2. Most common adverse events (occurring in >1 patient in either treatment group)

Preferred term	Pramlintide + insulin (*n* = 32)	Placebo + insulin (*n* = 28)
Nausea	14 (43.8)	2 (7.1)
Headache	8 (25.0)	1 (3.6)
Vomiting	6 (18.8)	0 (0.0)
Tremor	1 (3.1)	2 (7.1)
Anemia	0 (0.0)	4 (14.3)

Data are *n* (%).

SUPPLEMENTARY DATA

Supplementary Figure S1. Study design. B, breakfast; CSII, continuous subcutaneous insulin infusion; D, dinner; E, enrollment; EoS, end of study; HbA_{1c}, glycated hemoglobin; L, lunch; MDI, multiple daily injections; R, randomization; S, stabilization; SC, subcutaneous; V, visit.